- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Plymouth Meeting Today
By the People, for the People
HC Wainwright Issues Negative Estimate for HRMY Earnings
Analysts lower Q1 2026 earnings forecast for Harmony Biosciences
Published on Feb. 27, 2026
Got story updates? Submit your updates here. ›
Equity researchers at HC Wainwright have lowered their Q1 2026 earnings per share (EPS) estimates for shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY). The firm's analyst P. Trucchio now anticipates the company will post earnings of $0.76 per share for the quarter, down from their previous forecast of $0.86.
Why it matters
This downward revision in earnings estimates by a prominent research firm could signal potential challenges for Harmony Biosciences and impact investor sentiment around the stock. The company's financial performance is closely watched as it continues to commercialize its flagship product WAKIX.
The details
HC Wainwright maintained a "Buy" rating on Harmony Biosciences but lowered their price target to $55.00. The consensus estimate for the company's current full-year earnings is $2.43 per share. HC Wainwright also issued revised estimates for Harmony Biosciences' Q2 2026 ($0.92 EPS), Q3 2026 ($1.09 EPS), Q4 2026 ($1.31 EPS) and FY2030 ($7.07 EPS).
- On Wednesday, February 25th, HC Wainwright issued the revised earnings estimates.
The players
HC Wainwright
An American investment banking and securities firm that provides research coverage on Harmony Biosciences.
P. Trucchio
An analyst at HC Wainwright who covers Harmony Biosciences.
Harmony Biosciences Holdings, Inc.
A commercial-stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
The takeaway
This downward revision in earnings estimates by a prominent research firm could signal potential challenges for Harmony Biosciences and impact investor sentiment around the stock. The company's financial performance is closely watched as it continues to commercialize its flagship product WAKIX.
